A clinical study to evaluate the efficacy of Virechana karma and Punarnavadi Niruha Basti along with Shamana chikitsa in stage i and stage ii Chronic kidney disease -A continuous study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- PRIMARY OUTCOME WILL BE RELIEF IN SIGNS, SYMPTOMS AND ASSESSMENT WILL BE DONE WITH THE HELP OF CHANGES IN HB EGFR SERUM CREATININE BLOOD UREA SERUM ELECTROLYTES (SODIUM, POTASSIUM, CHLORIDE) SERUM CALCIUM SERUM PHOSPHATE URINE ROUTINE AND MICROSCOPIC.
研究概览
简要总结
The present study is a open labelled clinical study assessing the effectiveness of Ayurveda treatment for patients with chronic kidney disease (CKD) with serum creatinine levels between 1.4 mg/dL and 3.0 mg/dL. Conducted with 20 patients from the IPD of P. D. Patel Ayurveda Hospital, Nadiad, the study employed Shodhana Treatment (Virechana Karma and Niruha Basti) and specific oral formulations including Varunadi kwatha, Gokshuradiguggulu and Rasayana churna aimed at restoring Mutravaha Srotas functions and rejuvenating renal tissues. Findings showed significant improvements, with a marked reduction in symptoms such as edema and general weakness and an increase in kidney function markers, including eGFR and reduction in Serum creatinine, Blood urea and urine albumin . The study suggests that Ayurvedic treatments may decelerate CKD progression, potentially delaying the need for renal replacement therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.PATIENTS HAVING SERUM CREATININE LEVEL BETWEEN 1.4 MG/DL TO 3.0 MG/DL 2.PATIENTS INDICATED FOR VIRECHANA KARMA AND BASTI KARMA.
排除标准
- •1.FEMALE PATIENTS HAVING PREGNANCY, BREAST FEEDING OR POST-DELIVERY PERIOD 2.PATIENTS OF END STAGE KIDNEY DISEASE 3.PATIENTS WHO ARE ON DIALYSIS TREATMENT 4.PATIENTS WHO HAVING PREVIOUS HISTORY OF RENAL TRANSPLANTATION 5.PATIENTS OF HEPATO-RENAL INSUFFICIENCY OR RENAL INSUFFICIENCY DUE TO HAEMODYNEMIC CIRCULATORY DISORDERS AND CCF 6.PATIENTS WITH SOME SERIOUS ILLNESS LIKE CARDIO-VASCULAR DISEASES, PSYCHOLOGICAL DISORDERS, SERIOUS ACUTE ORGANIC DISEASES, SERIOUS CHRONIC CO-MORBIDITIES, LIVER DISORDERS OR METABOLIC DISORDERS ETC 7.PATIENTS WITH ANY BLEEDING DISORDERS 8.PATIENTS CONTRAINDICATED FOR VIRECHANA KARMA AND BASTI KARMA.
结局指标
主要结局
PRIMARY OUTCOME WILL BE RELIEF IN SIGNS, SYMPTOMS AND ASSESSMENT WILL BE DONE WITH THE HELP OF CHANGES IN HB EGFR SERUM CREATININE BLOOD UREA SERUM ELECTROLYTES (SODIUM, POTASSIUM, CHLORIDE) SERUM CALCIUM SERUM PHOSPHATE URINE ROUTINE AND MICROSCOPIC.
时间窗: 38-42 DAYS
次要结局
- SECONDARY OUTCOME WILL BE IMPROVEMENT IN THE KIDNEY FUNCTION OF THE PATIENTS(every 15 days up to 2 months)